Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry

Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry

BACKGROUND AND OBJECTIVES: Oral delayed-release dimethyl fumarate (DMF) is not recommended during pregnancy and should only be used if the potential benefit justifies the potential fetal risk. Although DMF was well tolerated in clinical trials with consistent safety results in postmarketing surveill...

Full description

Bibliographic Details
Main Authors: Branco, F. (Author), Bruen, D.R (Author), Everage, N.J (Author), Hellwig, K. (Author), Houtchens, M.K (Author), McGuigan, C. (Author), Mokliatchouk, O. (Author), Peng, X. (Author), Rog, D. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
adult
Adult
clinical trial
dimethyl fumarate
Dimethyl Fumarate
female
Female
human
Humans
immunosuppressive agent
Immunosuppressive Agents
pregnancy
Pregnancy
pregnancy complication
Pregnancy Complications
pregnancy outcome
Pregnancy Outcome
Prospective Studies
prospective study
register
Registries
young adult
Young Adult
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items